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are substrates of the nucleoside transport systems
• These transporters may therefore contribute to the 
absorption, disposition, efficacy or toxicity of these drugs
– e.g. Ribavirin: hemolytic anemia
Fialuridine: hepatotoxicity
• To better guide the future development of nucleoside 
drugs, the contribution of the nucleoside transporters to 







• Research Design, Methods and Preliminary Results
– Ex vivo Erythrocyte Transport of Ribavirin




• Endogenous role in nucleoside salvage for nucleotide 
biosynthesis and autocrine and paracrine cellular 
signaling
• Two major families:
Na+-independent
Low affinity/high capacity
Three members: ENT1, ENT2, ENT3
Equilibrative nucleoside transporters (ENTs)
Baldwin, S.A., et al. Pflugers Arch. – Eur. J. Physiol. (2004) 447: 735-743
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Nucleoside Transporters
• Two major families:
Na+-dependent
High affinity/low capacity
Three members: CNT1, CNT2, CNT3
Concentrative nucleoside transporters (CNTs)














(Ribavirin IC50 of [
3H]-inosine uptake 
in hENT1 expressed in yeast)
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Drug Transporters
Role of Tissue Distribution on Drug Disposition














































• Research Design, Methods and Preliminary Results
– Ex vivo Erythrocyte Transport of Ribavirin





• Ribavirin is used as first line treatment of compensated 
chronic hepatitis C virsus (HCV) infection and is co-
administered with interferon-α at doses of 800 to 1200 
mg/kg/day
• The dose-limiting toxicity of ribavirin is hemolytic anemia, 
occurring in 10-13% of patients
• Ribavirin is contraindicated in pregnancy because of 
teratogenicity observed in animals an in case reports
FDA Revised Label. Rebetol® (2004)




• The Cmax after a single oral dose of ribavirin was: 9.9 µM.
• After discontinuation of an intravenous infusion to steady-state, the 
plasma concentration time profile exhibited tri-exponential 
pharmacokinetics with half-lives of:
α: 0.2 - 0.9 hours
β: 1.6 - 2.0 hours
γ: 35.5 – 60 hours
• After discontinuation of oral dosing to steady-state, the terminal 
elimination half-life was:
λz: 298 hours
and ribavirin steady-state concentrations exhibited approximately 6-
fold accumulation (compared to after a single oral dose).
Laskin et al. Clin. Pharmacol. Ther. (1987) 41: 546-555
FDA Revised Label. Rebetol® (2004)




• The systemic clearance of ribavirin is 280-400 mL/min
• The renal clearance of ribavirin is 99 mL/min
• Ribavirin is completely unbound (0 ± 7%), and is not 
saturated between 1 and 50 µM
• The Vss of ribavirin after oral dosing is approximatley 650 
to 1100 L
• The oral bioavailability of ribavirin is 33 to 64%
Laskin et al. Clin. Pharmacol. Ther. (1987) 41: 546-555
FDA Revised Label. Rebetol® (2004)




























































































• In M. mulatta (Rhesus macaques) 8 hours after receiving 
[14C]-ribavirin by intramuscular and intravenous 
administration, the recovery of total radioactivity in the 
major organs of distribution was (% of total body 
radioactivity):
– 37.1 % in skeletal muscle
– 14.1 % in erythrocytes
– 8.1 % in the liver
minor amounts were recovered in:
– 1.0 % kidneys
– 0.5 % brain
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Ribavirin stimulated inward current in X. 
laevis oocytes expressing hCNT3 
Ribavirin
Vmax: 638 ± 58.1 nA
Km: 59.7 ± 17.5 µM
hCNT2 Mediated [3H]-
inosine uptake in human 
BBMVs
Inhibition of [3H]-uridine transport, and ribavirin
stimulated inward current in X. laevis oocytes
expressing hCNT1




“The mouse equilibrative nucleoside transporter 1 (mEnt1) 
significantly contributes to the absorption, tissue 
distribution, elimination and toxicity of ribavirin.”
Specific Aims
1. To characterize the ex vivo transport of [3H]-ribavirin in erythrocytes 
from mEnt1(+/+) and mEnt1(-/-) mice. 
2. To characterize the pharmacokinetics and tissue distribution of 
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Ex vivo Erythrocyte Transport of Ribavirin
Introduction
• The goal of this aim is to characterize the transport 








Ex vivo Erythrocyte Transport of Ribavirin
Experimental Design
• Mouse erythrocytes were washed in transport buffer and used within 
2 hours of collection
• Transport was initiated by adding 0.77 µM [3H]-ribavirin to 
erythrocytes in transport buffer (20% hematocrit), and stopped by 
dilution the suspensions 5-fold in transport buffer containing 10 mM 
NBMPR.  The erythrocytes were immediately pelleted into an oil-
layer (“oil-stop”), to limit further diffusional uptake
• Transport rates were calculated and normalized to total total protein 
amount
• Kinetic parameters (Vmax and Km) were determined using a “tracer-
displacement” analysis
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Ex vivo Erythrocyte Transport of Ribavirin
PCR Genotyping Assay of mEnt1 in Mice
Slc29a1 (NT_039655)
Ex 2 Ex 3 Ex 4
mEsG- 3 mEsG- 4
997 bp




Wild-type ( + ) allele
Knock-out ( -
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Ex vivo Erythrocyte Transport of Ribavirin
























Solid Bars: Water Spike
Open Bars: Erythrocyte Spike
Decolorization with 30% H2O2
restores reduced recovery of 
erythrocyte spikes  
92 ± 2%
102 ± 2%100 ± 2% 103 ± 2%
Color quenching by 
erythrocytes reduced recovery 
of erythrocyte spikes  
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Ex vivo Erythrocyte Transport of Ribavirin




































Values represent mean ± S.D. (n=3)
Filled: Vehicle
Open: 10 µM NBMPR
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Ex vivo Erythrocyte Transport of Ribavirin








































[3H]-Ribavirin Uptake After 10 Seconds of Transport
Values represent mean ± S.D. (n=3)
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Ex vivo Erythrocyte Transport of Ribavirin
Ribavirin Transport Kinetics in Erythrocytes
Values represent mean ± S.D. (n=3)
Tracer Displacement Kinetics Analysis
Mean ± S.D. (n=4)
382 ± 75.1 µM
Km
417 ± 86.7 amol/µg/10 sec
Vmax
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Ex vivo Erythrocyte Transport of Ribavirin
Conclusions
• The time-course of [3H]-ribavirin uptake in mEnt1(+/+) erythrocytes 
rapidly reaches equilibrium within 60 seconds, and was completely 
inhibited by 10 µM NBMPR.
• There is no NBMPR inhibitable [3H]-ribavirin transport in 
erythrocytes from mEnt1(-/-) mice.
• The transport activity of the mEnt1(+/-) erythrocytes was 
approximately half that of the mEnt1(+/-) erythrocytes, suggesting a 
gene-dose effect on activity.
• The Km of [
3H]-ribavirin transport in mEnt1(+/+) erythrocytes was 
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Pharmacokinetics and Tissue Distribution
Introduction
• The goal of this aim is to characterize the 
pharmacokinetics and tissue distribution of ribavirin in 
mEnt1(+/+) and mEnt1(-/-) mice.
• We will estimate pharmacokinetic parameters after both 
oral and intravenous administration of  [3H]-ribavirin
• We will examine the tissue distribution of [3H]-ribavirin 
after intravenous administration in tissues where mEnt1 
expression may be important in drug distribution:
i.e. liver, intestine, kidney, brain, skeletal muscle, heart and
pancreas
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Pharmacokinetics and Tissue Distribution
Experimental Design
• [3H]-Ribavirin was administered orally (10 µg/g) or 
intravenously (3 µg/g) to mEnt1(+/+) and mEnt1(-/-) 
mice.
• Plasma, and erythrocyte samples were obtained by 
retro-orbital bleeding 15, 30, 60, 120, 240, 480, 720 and 
1440 minutes after administration
• Ribavirin concentrations were determined by:
– Direct counting for total radioactivity
– HPLC / Fraction collection to determine percent ribavirin
composition of the total radioactivity (t.b.d)
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Pharmacokinetics and Tissue Distribution
Experimental Design
• Tissues were collected at necropsy and concentrations 
were determined using a similar methodology (direct 
counting/HPLC fraction collection).
• [14C]-Sucrose (tracer dose, 0.05 µCi/g) was administered 
to correct tissue ribavirin concentrations for ribavirin
present in the tissue vascular volume.
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Pharmacokinetics and Tissue Distribution


















































Fluid Spike Recovery Tissue Spike Recovery
Solid bars: [3H]-Ribavirin
Open bars: [14C]-Sucrose
Values represent mean ± S.D. percent recovery
n=3 
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Pharmacokinetics and Tissue Distribution









































































Values represent mean ± S.D. percent recovery
n=2-3 




Pharmacokinetics and Tissue Distribution















































































Intravenous [3H]-Rivavirin Dose (3 µg/g; 0.4 µCi/g)













































Values represent mean ±
S.D. percent recovery, n=2-3 
Intravenous [14C]-Sucrose Dose (0.05 µCi/g)
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Pharmacokinetics and Tissue Distribution

























































Total Radioactivity Liver : Plasma Ratio
Data correct for vascular contribution of [3H]-total radioactivity 




Liver [3H]-Total Radioactivity Concentration (µCi/g tissue) 15 Minutes After 3 




Pharmacokinetics and Tissue Distribution
Conclusions
• There is an 8-fold decrease in hepatic distribution in the 
mEnt1(-/-) mice
– This is consistent with mEnt1 expression on the hepatic 
sinusoidal membrane,
– and mEnt1 mediated hepatic uptake of ribavirin
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Pharmacokinetics and Tissue Distribution
Conclusions
• The plasma [3H]-total radioactivity concentrations were 
greater in the mEnt1(-/-) mice than the mEnt1(+/+) mice 
consistent with decreased distribution to the peripheral 
compartment(s) in the mEnt1(-/-) mice.
• The erythrocyte [3H]-total radioactivity concentrations 
were greater in the mEnt1(+/+) mice than the mEnt1(-/-) 
mice, consistent with reduced uptake in the mEnt1(-/-) 
mice.  Surprisingly, the magnitude of this difference was 






• Research Design, Methods and Preliminary Results
– Ex vivo Erythrocyte Transport of Ribavirin




• mEnt1 contributes to erythrocyte uptake of ribavirin ex 
vivo.
• mEnt1 significantly contributes to the hepatic and 
erythrocyte distribution of ribavirin in vivo
• Because of this, the ENT1 may also play an important 
role in other tissue distribution, elimination and toxicity of 
ribavirin and other nucleoside drugs.
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Future Directions
• Validate HPLC assay for [3H]-ribavirin quantitation from 
fluids and tissue
• Complete I.V. ribavirin pharmacokinetics and tissue 
distribution
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